Avelumab plus axitinib combintion approved for untreated advanced kidney cancer in Scotland
The Sottish Medicine Consortium (SMC) have issued a final decision to recommend the avelumab plus axitinib combination for untreated advanced kidney cancer for patients in Scotland. We are delighted that as from today, kidney cancer patients in Scotland can get NHS funding for avelumab in combination with axitinib for the first-line treatment of patients with advanced or metastatic renal cell carcinoma […]